

the presence of BS200 mRNA in breast tissue, suggesting a diagnosis of a breast tissue disease or condition, such as breast cancer.

REMARKS

Entry of this Amendment is respectfully requested.


This Amendment is being submitted in response to the "Notice of Drawings Inconsistency With Specification" mailed on April 21, 2003 in connection of the above-identified application.

This Amendment seeks to correct the drawing inconsistency in connection with this application. Specifically, references to Figures 3A-3B on page 11 of the specification has been deleted. The references to Figures 3A and 3B on page 68 has been rewarded to remove the references to these Figures. Applicants submit that these amendments to the specification do not involve any new matter. Also, Applicants submit that Figures 3A-3B are not necessary for an understanding of the invention and therefore were not necessary under 35 U.S.C. §113 for a filing date.

If any additional fees are incurred as the result of the filing of this paper, authorization is given to charge the deposit account no. 23-0785.

Respectfully submitted,

Billing-Medel, et al.



Lisa V. Mueller
Attorney for Applicants
Reg. No. 38,978

Wood, Phillips, Katz, Clark & Mortimer
500 West Madison St., Suite 3800
Chicago, IL 60661
Phone: (312) 876-1800

MARKED UP VERSION SHOWING CHANGES MADE:

IN THE SPECIFICATION:

On page 11, please delete lines 9-13.

Please amend page 68, lines 4-17 to read as follows:

C. PCR Fragment Analysis. The correct products were verified by size determination using gel electrophoresis with ethidium bromide staining (0.5 µg/ml) and visualized by UV illumination [(Figures 3A and 3B)]. [Figure 3A shows] PCR generated DNA bands of approximately 332 bp, as indicated by DNA size markers [(Lane 6)], which are indicative of a BS200-specific PCR product in normal breast tissue [(lanes 1-5)], breast cancer tissue [(lanes 8, 9, and 11)], were observed, and the MCF7 cell line [(lane 11)] but not [from] in placental DNA [(lane 14)]. [Figure 3B shows that the]The BS200-specific band at 332 bp was not observed in the five normal lung and lung cancer tissues tested [(lanes 1-5)], nor in the five normal colon and colon cancer tissues tested [(lanes 7-11)]. Detection of a product comprising a sequence selected from the group consisting of SEQUENCE ID NOS 1-16, and fragments or complements thereof, indicates the presence of BS200 mRNA in breast tissue, suggesting a diagnosis of a breast tissue disease or condition, such as breast cancer.